AD, PD and ALS
T/R 8:30-10:00; 1st half of Spring 2009
Course SummaryTEXTBOOK: None. All readings will be assigned from the primary literature. Sometimes videos will be assigned in lieu of readings.
SYLLABUS: Click here.
COURSE WIKI: This course made use of a wiki (www.pbwiki.com) for distributing updated versions of the syllabus and for collecting student blogs and questions for discussion. We highly recommend using a tool like this. PB wiki comes in free and paid versions, depending on your needs.
Viewing the Lectures from 2009From a PC: Just click on the link
From a Mac: download - just once - a copy of silverlight.
Lectures - Spring 2009
|Lecture Title||Lecturer||Date||Video/Slide Presentation|
|Clinical presentation of AD; diagnostic criteria; AD biomarkers: biochemical and imaging||Steven Arnold, MD||Jan 15||Video/Slides|
|AD Genetics||Jerry Schellenberg, PhD||Jan 20||Video/Slides|
|Protein misfolding as a common mechanism among many neurodegenerative disorders; Overview of clinical trials in AD (inclu. which pathophysiological mechanisms were targeted)||Virginia M.Y. Lee, PhD||Jan 22||Video/Slides|
|Mechanisms of AD pathogenesis and pathophysiology, e.g. amyloid cascade hypothesis, tau, and the therapeutic approaches they suggest. Review of recently completed clinical trials and of the NSAID (non-steroidal anti-inflammatory) trial.||Virginia M.Y. Lee, PhD||Jan 27||Video/Slides|
|Tau: involvement in AD and FTD (fronto-temporal dementia). Potential tau and tau-related (e.g. MT stabilizing, kinase inhibiting) therapeutics.||John Trojanowski MD, PhD||Jan 29||Video/Slides|
|Glutamate toxicity and the role of glutamate transporters. Examples of glutamate modulators as therapeutic agents||Mike Robinson, PhD||Feb 3||Video/Slides|
|Parkinson's Disease: Clinical overview and review of clinical trials||Nabila Dahodwala, MD||Feb 5||Video/Slides|
|Parkinson's Disease: genetics - alpha synuclein, parkin, DJ1, PINK1, and LRRK2. Gauchier's mutations. Gene therapy for PD.||Vivianna Van Deerlin, MD, PhD||Feb 10||Video/Slides|
|Parkinson's Disease: pathological mechanisms; review of mechanisms upon which clinical trials and medications have been based: e.g. antioxidants (monoamine oxidase B inhibitor, Co Q10 etc); dopamine agonists, Catechol-O-methyl transferase (COMT) inhibitors, NMDA receptor antagonists||Benoit Giasson, PhD||Feb 12||Video/Slides|
|Oxidative stress: Role across various neurodegenerative disorders and role as potential therapeutic agents.||Harry Ischiropolous, PhD||Feb 17||Video/Slides|
|Clinical overview of FTD and ALS||Murray Grossman, MD||Feb 19||Video/Slides|
|TPD43: a newly identified pathological protein in sporadic ALS. Pathology, pathological mechanisms, genetics; imagining a "bench to bedside" story||Virginia M.Y. Lee, PhD||Feb 24||Video/Slides|
|Student Presentations||-||Feb 26|
|Student Presentations||-||Mar 3|
|Student Presentations||-||Mar 5|